Company / EPS (Diluted)
Acadia Pharmaceuticals EPS (Diluted) History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest EPS (Diluted)
-$0.37
FY2025
5-year range
-$1.79 / -$0.37
FY2021-FY2025
Trend
+72.4%
vs FY2024
Sector context
#61 of 204
Health Care
What the data says
At $-0.37, Acadia Pharmaceuticals's eps (diluted) ranks #61 of 204 in the Health Care sector. EPS (Diluted) has fluctuated over the past 10 years, ranging from $-2.36 in FY2019 to $-0.37 in FY2025.
Based on SEC 10-K filings.
-0.37 in FY2025.
Improved from $-1.05 to $-0.37 over the past 2 years.
Health Care sector context is included.
EPS (Diluted) over time
Growth rates
- 3-Year CAGR
- -
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Sector benchmark
#61 of 204 in Health CareTop 30% of 204This company -$0.37 Sector average -$0.98
▼
+62.2% above sector average
Key checks
Key Insights
- In FY2025, eps (diluted) increased 72.4% year-over-year.
- Ranks #61 out of 204 companies in the Health Care sector.
- Lowest eps (diluted) in the period was in FY2019.
Company context
Key Data Points
- Strong profit margin: 24.9%
- Low earnings quality (accrual-heavy earnings)
- Strong return on equity: 28.5%
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | EPS (Diluted)Value | YoY GrowthYoY |
|---|---|---|
| FY2025 | -$0.37 | +72.4% |
| FY2024 | -$1.34 | -27.6% |
| FY2023 | -$1.05 | +41.3% |
| FY2022 | -$1.79 | -11.9% |
| FY2021 | -$1.60 | +17.5% |
| FY2020 | -$1.94 | +17.8% |
| FY2019 | -$2.36 | -0.9% |
| FY2018 | -$2.34 | -43.6% |
| FY2017 | -$1.63 | -71.6% |
| FY2016 | -$0.95 | -115.9% |
As of FY2025 · SEC 10-K · Updated Jul 1, 2026